PRME vs. BEAM

Last updated Jun 23, 2026

PRME (Prime Medicine Inc. Common Stock) and BEAM (Beam Therapeutics Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 3 years, PRME returned -39.21%/yr vs 3.76%/yr for BEAM. A 0.57 correlation means they provide meaningful diversification when combined.

Performance

PRME vs. BEAM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Prime Medicine Inc. Common Stock (PRME) and Beam Therapeutics Inc. (BEAM). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PRME achieves a -2.88% return, which is significantly lower than BEAM's 28.17% return.

PRME

• 1D: 4.33%
• 1M: 13.47%
• YTD: -2.88%
• 6M: -8.92%
• 1Y: 62.80%
• 3Y*: -39.21%
• 5Y*: —
• 10Y*: —

BEAM

• 1D: 4.07%
• 1M: 24.06%
• YTD: 28.17%
• 6M: 27.26%
• 1Y: 111.99%
• 3Y*: 3.76%
• 5Y*: -16.23%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PRME vs. BEAM - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
PRME Prime Medicine Inc. Common Stock	-2.88%	18.84%	-67.04%	-52.31%	-2.06%
BEAM Beam Therapeutics Inc.	28.17%	11.77%	-8.89%	-30.40%	-12.80%

Correlation

The correlation between PRME and BEAM is 0.63, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.63
Correlation (3Y) Calculated over the trailing 3-year period	0.60
Correlation (All Time) Calculated using the full available price history since Oct 20, 2022	0.57

The correlation between PRME and BEAM has been stable across timeframes, ranging from 0.57 to 0.63 - a consistent structural relationship.

Fundamentals

Market Cap PRME : $596.81M BEAM : $3.67B
EPS PRME : -$1.29 BEAM : -$0.63
PS Ratio PRME : 163.18 BEAM : 27.72
PB Ratio PRME : 7.78 BEAM : 3.15
Total Revenue (TTM) PRME : $3.18M BEAM : $132.27M
Gross Profit (TTM) PRME : -$4.14M BEAM : -$84.92M
EBITDA (TTM) PRME : -$195.72M BEAM : -$68.39M

Return for Risk

PRME vs. BEAM — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRME

PRME Risk / Return Rank: 64
PRME Sharpe Ratio Rank: 63
PRME Sortino Ratio Rank: 69
PRME Omega Ratio Rank: 63
PRME Calmar Ratio Rank: 64
PRME Martin Ratio Rank: 59

BEAM

BEAM Risk / Return Rank: 81
BEAM Sharpe Ratio Rank: 82
BEAM Sortino Ratio Rank: 82
BEAM Omega Ratio Rank: 77
BEAM Calmar Ratio Rank: 83
BEAM Martin Ratio Rank: 80

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRME vs. BEAM - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and Beam Therapeutics Inc. (BEAM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PRME	BEAM	Difference
Sharpe ratio: Return per unit of total volatility	0.66	1.49	-0.84
Sortino ratio: Return per unit of downside risk	1.64	2.39	-0.75
Omega ratio: Gain probability vs. loss probability	1.17	1.27	-0.10
Calmar ratio: Return relative to maximum drawdown	1.06	2.95	-1.89
Martin ratio: Return relative to average drawdown	1.66	6.34	-4.69

PRME vs. BEAM - Sharpe Ratio Comparison

The current PRME Sharpe Ratio is 0.66, which is lower than the BEAM Sharpe Ratio of 1.49. The chart below compares the historical Sharpe Ratios of PRME and BEAM, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PRME vs. BEAM - Drawdown Comparison

The maximum PRME drawdown since its inception was -94.55%, which is greater than BEAM's maximum drawdown of -89.12%. Use the drawdown chart below to compare losses from any high point for PRME and BEAM.

Drawdown Indicators

	PRME	BEAM	Difference
Max Drawdown Largest peak-to-trough decline	-94.55%	-89.12%	-5.43%
Max Drawdown (1Y) Largest decline over 1 year	-59.52%	-38.15%	-21.37%
Max Drawdown (3Y) Largest decline over 3 years	-92.37%	-67.74%	-24.63%
Max Drawdown (5Y) Largest decline over 5 years	—	-89.12%	—
Current Drawdown Current decline from peak	-84.04%	-73.41%	-10.63%
Average Drawdown Average peak-to-trough decline	-65.61%	-59.93%	-5.68%
Ulcer Index Depth and duration of drawdowns from previous peaks	38.02%	17.72%	+20.30%

Volatility

PRME vs. BEAM - Volatility Comparison

Prime Medicine Inc. Common Stock (PRME) has a higher volatility of 26.45% compared to Beam Therapeutics Inc. (BEAM) at 23.00%. This indicates that PRME's price experiences larger fluctuations and is considered to be riskier than BEAM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PRME	BEAM	Difference
Volatility (1M) Calculated over the trailing 1-month period	26.45%	23.00%	+3.45%
Volatility (6M) Calculated over the trailing 6-month period	53.90%	53.52%	+0.38%
Volatility (1Y) Calculated over the trailing 1-year period	96.08%	75.50%	+20.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	90.38%	76.10%	+14.28%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	90.38%	80.82%	+9.56%

Dividends

PRME vs. BEAM - Dividend Comparison

Neither PRME nor BEAM has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both PRME and BEAM in my portfolio?

PRME and BEAM have a correlation of 0.63, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PRME or BEAM?

PRME has higher volatility (26.45%) compared to BEAM (23.00%). In terms of maximum drawdown, PRME dropped -94.55% vs BEAM's -89.12%.

Which has better risk-adjusted returns?

BEAM currently has the higher Sharpe Ratio (1.49 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.